cyc 682 has been researched along with cytarabine in 7 studies
| Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (cytarabine) | Trials (cytarabine) | Recent Studies (post-2010) (cytarabine) |
|---|---|---|---|---|---|
| 30 | 5 | 18 | 15,487 | 2,424 | 3,188 |
| Protein | Taxonomy | cyc 682 (IC50) | cytarabine (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 7.533 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanaoka, K; Hisaoka, M; Ikeda, T; Iwabuchi, H; Kaneko, M; Kobayashi, T; Kurakata, S; Matsuda, A; Mitsuhashi, Y; Miura, S; Nakagawa, A; Nomura, T; Sasaki, T; Shibayama, T; Suzuki, M; Tanaka, K; Tanzawa, F; Tomida, A; Tsuruo, T; Wataya, Y | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Burnett, AK; Hills, RK | 1 |
| Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ | 1 |
| Burnett, AK; Cahalin, P; Clark, RE; Hemmaway, C; Hills, RK; Khwaja, A; Milligan, D; Panoskaltsis, N; Russell, N | 1 |
| Al Abo, M; Huang, SY; Kiselev, E; Liu, X; Plunkett, W; Pommier, Y; Rajapakse, VN; Sasanuma, H; Takeda, S | 1 |
1 review(s) available for cyc 682 and cytarabine
| Article | Year |
|---|---|
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
1 trial(s) available for cyc 682 and cytarabine
| Article | Year |
|---|---|
A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cytarabine; Cytosine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate | 2015 |
5 other study(ies) available for cyc 682 and cytarabine
| Article | Year |
|---|---|
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformation; Breast Neoplasms; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; KB Cells; Leukemia P388; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Mitomycin; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Rats, Nude; Specific Pathogen-Free Organisms; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine | 1999 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Gemcitabine; Homologous Recombination; Inhibitory Concentration 50; Prodrugs | 2012 |
TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Topics: Arabinonucleosides; BRCA2 Protein; Camptothecin; Colorectal Neoplasms; Cytarabine; Cytosine; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA Replication; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Phosphoric Diester Hydrolases; Poly (ADP-Ribose) Polymerase-1 | 2017 |